Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
Introduction
The main objective of the study is to vaccinate patients with metastatic breast cancer with a viable dendritic cell (DC)/breast cancer fusions in conjuction with IL-12 to induce an immunological response with the hope that this combination would further enhance vaccine response by promoting Th1 cytokine induction and T cell activation. In this approach, the entire repertoire of tumor antigens, including those yet to be identified, are expressed with the immune-stimulating machinery of the DCs. The fusion cell vaccine allows for induction of helper T and CTL responses by class II presentation of exogenous protein and class I presentation of newly synthesized endogenous protein. Several of our clinical studies have demonstrated that vaccination with fusion cells was well tolerated, induced immunologic responses in a majority of patients, and results in disease regression in subset of patients. This brief report details the characterization of tumor cells and dendritic cells generated from patient BV01 with metastatic breast cancer following isolation from pleural effusions and leukapheresis, respectively.
Clinical Trial
Following completion of a review by the DOD, IRB and the FDA, patients were enrolled in the activated protocol and generations of DC/tumor fusion vaccine was initiated. During the last quarter, 5 patients have been enrolled in the trial. A detailed characterization of the tumor cells, the generated dendritic cells and the DC/tumor fusions pertaining to Patient BV01 was described in detail in the previous report. In the current report, we present detailed immune data following completion of vaccination of Patient BV01.
Immune monitoring of Patient BV01:

Induction of tumor-reactive lymphocytes by DC/breast cancer cell fusion vaccine
To assess the effects of fusion cell vaccination on the capacity of patients to mount a tumorspecific CTL response, we measured the immunologic response to vaccination by determining the percentage of circulating CD4 + and CD8 + T cells that recognize autologous breast carcinoma cells as manifested by the percentage of cells that express IFN-γ after exvivo exposure to autologous tumor lysate. Immunologic assessments were performed before each vaccination (three time points) and at one month after the last vaccine. The peak response after vaccination was compared with pre-vaccination levels of tumor-reactive T cells to assess the fold increase in tumor-reactive T cells after vaccination. At each time point, mononuclear cells were isolated from peripheral blood by Ficoll density centrifugation and cryopreserved. After completion of the study, PBMCs were thawed, and 1 × 10 6 cells were cultured with lysate generated by repeated freeze/thaw cycles of 1 × 10 5 autologous breast carcinoma cells. As a control, PBMCs were cultured with tetanus toxoid (10 μg/mL) or media alone. After 5 days of coculture, expression of IFN-γ by CD4 + and CD8 + populations was determined by intracellular FACS analysis. Cells were restimulated with tumor lysate for 4 hours in the presence of 1 μg/mL GolgiStop (BD Biosciences). The cells were stained with FITC-conjugated CD4 or CD8 antibodies and permeabilized with Cytofix/Cytoperm Plus (BD Biosciences). Cells were thereafter stained with PE-conjugated anti-human IFN-γ, fixed in 2% paraformaldehyde, and analyzed by flow cytometry. A slight increase in the percentage of CD4 and CD8 T cells expressing IFNγ was observed at the pre-vaccination #2 time point, but this response tapered off after the patient received the third vaccine. 
Vaccine potency and Phytohemagglutinin and tetanus-induced induced T-cell proliferation
As a measure of potency of the generated vaccine as antigen-presenting cells, the capacity of the DC, breast carcinoma, and fusion cells to stimulate proliferation of allogeneic T cells was measured as shown below. In addition, freshly isolated patient PBMCs (1 × 10 5 ) isolated at serial time points (as outlined above) were cocultured in 200 μl of medium in 96-well U-bottomed plates for 4 days with 4 μg/ml PHA and tetanus toxoid (10 μg/mL (Figure 2, below) . Proliferation was determined by measuring incorporation of [ 
Cocultures were incubated for 5 days, and T-cell proliferation was determined by incorporation of [ 3 H]-thymidine (1 μCi/well) after overnight pulsing. Stimulation index (SI) represents counts per minute (CPM) of sample per CPM of unstimulated T cells.
Quantification of regulatory T cells
As outlined above, PBMCs were isolated at serial time points pre-and post-vaccination, and regulatory T cells were quantified by determining the percentage of CD4/CD25 high T cells by bidimensional FACS analysis (Figure 3) . Expression of FOXP3 by CD4/CD25 cells was measured in by intracellular FACS analysis (Figure 4) . No significant changes were observed in the expression of CD4/CD25
high T cells at pre-surgery and post-vaccination time points. Similarly, the expression of CD4/CD25 expressing FOXP3 did not change dramatically as depicted in Figure 3 . 
Conclusion
In the present study, patient BV01 with metastatic breast cancer was vaccinated with fusion cells generated from patient-derived tumor cells and autologous DCs. The results show that both CD4 and CD8 T cells expressed IFNγ post-vaccination suggesting an establishment of anti-tumor activity that tapered off at 1 month post-vaccination # 3. Furthermore, weak responses to PHA and Tetanus Toxoid were observed post vaccination, whereas, no dramatic change was observed in the levels of regulatory T cells or those that expressed FOXP3 pre-and post-vaccination.
